Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 4/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.71 |
| ▸ | NPC1 | O15118 | 8/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | AHR | P35869 | 1/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.67 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pifexole SCHEMBL2110643 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| Pifexole SCHEMBL29897050 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL3429701 | 0.82 | RAB9A (0.77) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL29858972 | 0.82 | RAB9A (0.77) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL23288072 | 0.82 | ALDH1A1 (0.74) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL1422846 | 0.82 | ALDH1A1 (0.74) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL2463534 | 0.81 | SMN1; SMN2 (0.93) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL1422890 | 0.81 | CHRNB2 (1.00) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL1424887 | 0.80 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53ALDH1A1MAPTTSHR | |
| SCHEMBL9505522 | 0.79 | NPC1 (0.70) | SMN1; SMN2TP53ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SMN1; SMN2 1279/4885TP53 4795/4885ALDH1A1 3466/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SMN1; SMN2 1279/4885TP53 4795/4885ALDH1A1 3466/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SMN1; SMN2 1279/4885TP53 4795/4885ALDH1A1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.